GlassScriptPhysician profile
James Lenhart
NPI 1326037391
$3,097.90
in general payments reported to CMS, 2019-2025
21 companies · $663 in 2025
The $663 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $159 · 2021: $450 · 2022: $450 · 2023: $533 · 2024: $394 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $319.88 | 2023-2025 | Miebo, Vyzulta, Infuse |
| Johnson & Johnson Vision Care, INC. | $311.42 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $300.23 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $259.61 | 2022-2025 | Dextenza |
| Alcon Vision LLC | $248.67 | 2019-2023 | Eysuvis |
| Rxsight INC | $245.81 | 2022-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Aerie Pharmaceuticals, INC. | $243.47 | 2019-2021 | |
| Glaukos Corporation | $242.85 | 2019-2023 | |
| Abbvie INC. | $186.48 | 2023-2025 | |
| Ivantis, INC | $136.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $91.67 | 2019 | |
| Genentech USA, INC. | $90.23 | 2020 | |
| Allergan, INC. | $89.08 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $45.64 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.19 | 2019 | |
| Dompe US, INC. | $32.32 | 2024 | Oxervate |
| Coopervision INC. | $27.22 | 2020-2023 | Myday Contact Lens |
| Biotissue Holdings INC. | $25.00 | 2025 | |
| Kala Pharmaceuticals, INC. | $23.47 | 2022 | |
| Omeros Corporation | $18.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lenhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.